|
US2005026194A1
|
|
Gene amplification and overexpression in cancer
|
|
WO2004091479A2
|
|
Gene amplification and overexpression in cancer
|
|
ZA200402021B
|
|
Linked biaryl compounds.
|
|
AU2003254064A8
|
|
Amplification and overexpression of oncogenes
|
|
AU2002359697A1
|
|
Identification of an amplified gene and target for drug intervention
|
|
US6809104B2
|
|
Fused heterocyclic compounds
|
|
AU2002356898A1
|
|
Gene amplification and overexpression in cancer
|
|
US2003171399A1
|
|
Quinolinyl and benzothiazolyl modulators
|
|
US2003149108A1
|
|
Linked biaryl compounds
|
|
WO03018769A2
|
|
Amplified gene involved in cancer
|
|
EP1421214A2
|
|
Amplified oncogenes and their involvement in cancer
|
|
AU2002346030A1
|
|
Novel receptors
|
|
US6794379B2
|
|
CXCR3 antagonists
|
|
WO02094264A1
|
|
Ccr4 antagonists
|
|
AU2002305323A1
|
|
Fused heterocyclic compounds
|
|
WO02077001A2
|
|
Novel receptors
|
|
AU2002258400A1
|
|
Methods of using pyrimidine-based antiviral agents
|
|
AU2002251919A1
|
|
Use of a farnesoid x receptor antagonist for treating hyperlipidemia
|
|
AU2002240336A1
|
|
Methods for the diagnosis and treatment of tumors employing the hepsin gene
|
|
AU2002250024A1
|
|
Prc17: an amplified cancer gene
|
